Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen TEPEZZA (teprotumumab-trbw by Year
TEPEZZA (teprotumumab-trbw — Thyroid Eye Disease) — Worldwide reported sales growth YoY (%) (%)
Amgen TEPEZZA (teprotumumab-trbw: 3.0% in FY2025.
Latest, FY2025
3.0%
Period ended Dec 31, 2025
Change on a year earlier
–
History
1 years
Since FY2025
Sources
1
Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03)
Where the FY2025 figure comes from
“|| TEPEZZA ® | 1,758 | 145 | 1,903 | 1,851 | 3%”
Source: Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Reported in Form 8-K Product Sales Detail by Product and Geographic Region.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | TEPEZZA (teprotumumab-trbw — Thyroid Eye Disease) — Worldwide reported sales growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.0% | – | Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗ |
Cite this data
StockData. (2026). Amgen TEPEZZA (teprotumumab-trbw (%), annual FY2025–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-tepezza-yoy
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.